Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 5/20 | 0.65 |
| ▸ | LCK | P06239 | 5/20 | 0.65 |
| ▸ | MET | P08581 | 5/20 | 0.65 |
| ▸ | TEK | Q02763 | 5/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | LYN | P07948 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746928 | 0.93 | KDR (0.69) | KDRFGFR2AURKALCKMET | |
| SCHEMBL2747380 | 0.92 | KDR (0.75) | KDRAURKALCKMETTEK | |
| SCHEMBL2746336 | 0.91 | KDR (0.72) | KDRFGFR2AURKALCKMET | |
| SCHEMBL2747364 | 0.91 | KDR (0.72) | KDRFGFR2AURKALCKMET | |
| SCHEMBL2747611 | 0.90 | KDR (0.72) | KDRAURKALCKMETTEK | |
| SCHEMBL2746837 | 0.90 | KDR (0.66) | KDRFGFR2AURKALCKMET | |
| SCHEMBL2747703 | 0.90 | KDR (0.72) | KDRFGFR2AURKALCKMET | |
| SCHEMBL4549024 | 0.90 | KDR (0.68) | KDRFGFR2AURKALCKMET | |
| SCHEMBL4549015 | 0.90 | KDR (0.71) | KDRFGFR2AURKALCKMET | |
| SCHEMBL2748366 | 0.90 | KDR (0.66) | KDRAURKALCKMETTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885FGFR2 26/4885AURKA 4148/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885FGFR2 26/4885AURKA 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.